2012
DOI: 10.1007/s12291-012-0234-7
|View full text |Cite
|
Sign up to set email alerts
|

Correlation of Levels of IL-6 with Tumor Burden and Receptor Status in Patients of Locally Advanced Carcinoma Breast

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(9 citation statements)
references
References 13 publications
(18 reference statements)
0
8
0
Order By: Relevance
“…TMB is correlated with clinical outcome in multiple cancer types treated with CPI (65,66). Previous studies indicated that TMB levels correlated with gene mutations in tumors (25,40,67,68). TMB-H has been reported to correlate with the generation of neoantigens and potential clinical responses to immunotherapies (69).…”
Section: Discussionmentioning
confidence: 99%
“…TMB is correlated with clinical outcome in multiple cancer types treated with CPI (65,66). Previous studies indicated that TMB levels correlated with gene mutations in tumors (25,40,67,68). TMB-H has been reported to correlate with the generation of neoantigens and potential clinical responses to immunotherapies (69).…”
Section: Discussionmentioning
confidence: 99%
“…Circulating pro-inflammatory cytokines are elevated in various cancer populations prior to any treatment including ovarian cancer (Lutgendorf et al, 2008), colorectal cancer (Belluco et al, 2000), lung cancer (Wojciechowska-Lacka, et al, 1996), breast cancer (Benoy et al, 2002), pancreatic cancer (Okada et al, 1998), gastric cancer (Kim et al, 2003), prostate cancer (Michalaki et al, 2004), head and neck cancer (Riedel et al, 2005), renal cell carcinoma (Yoshida et al, 2002), and bladder cancer (Mahmoud El-Salahy, 2002). High concentrations of circulating inflammatory cytokines such as IL-6 and TNF-α are associated with later stage disease (Belluco et al, 2000; Kim et al, 2003; Kozlowski et al, 2003; Michalaki et al, 2004; Okada et al, 1998; Yoshida et al, 2002), poorly differentiated tumors (Goswami et al, 2013; Kaminska et al, 2005; Ljungberg et al, 1997; Mahmoud El-Salahy, 2002; Yoshida et al, 2002) and tumor size/volume (Chung & Chang, 2003; Kaminska et al, 2005; Plante et al, 1994) in a variety of malignancies. Elevations of circulating pro-inflammatory cytokines have also been associated with less common indices of disease severity including extent of tumor necrosis in colorectal cancer (Guthrie et al, 2013; Richards et al, 2012).…”
Section: Cancer Patients Prior To Treatmentmentioning
confidence: 99%
“…Tumor Necrosis Factor alpha is one of the main cytokines secreted from the adipose tissue that increases the concentration of pro-inflammatory cytokines (CRP and IL-6); as a growth factor, it can induce tumor growth and cancer metastasis (8,9). The IL-6 expression in breast tissue is associated with the grade of the tumor (10,11). Previous studies have shown that, compared to healthy women, breast cancer survivors have higher amounts of circulating cytokines, a disorder that may persist for up to five years after the diagnosis of cancer (12).…”
Section: Introductionmentioning
confidence: 99%